TScan Therapeutics
TCRX
TScan Therapeutics (TCRX) news
Recent news
Tscan Therapeutics - termination of collaboration agreement effective November 10, 2026 - SEC filing
AInvest Wire · Aug 18, 2026Tscan Therapeutics 2Q loss/share 23c, est. loss/share 25c
TScan Therapeutics, Inc. (Nasdaq: TCRX) reported a net loss of $24.0 million for the second quarter ended June 30, 2023, translating to a loss per share of $0.51, according to its unaudited financial results. This compares to a net loss of $15.1 million , or $0.63 per share, for the same period in…
AInvest Wire · Aug 12, 2026Tscan Therapeutics has cash to fund ops into 2Q27
AInvest Wire · Aug 12, 2026Tscan Therapeutics - on track to enroll first patient in Phase 3 Aloha-2 study of TSC-101 this month
AInvest Wire · Jun 22, 2026Tscan Therapeutics - agreement adds TCR-T cell therapies to Cellares automated portfolio
AInvest Wire · Jun 3, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.